These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 22694102)
1. Molecular modeling study for conformational changes of Sirtuin 2 due to substrate and inhibitor binding. Sakkiah S; Chandrasekaran M; Lee Y; Kim S; Lee KW J Biomol Struct Dyn; 2012; 30(3):235-54. PubMed ID: 22694102 [TBL] [Abstract][Full Text] [Related]
2. Molecular docking and dynamics simulation, receptor-based hypothesis: application to identify novel sirtuin 2 inhibitors. Sakkiah S; Thangapandian S; Park C; Son M; Lee KW Chem Biol Drug Des; 2012 Aug; 80(2):315-27. PubMed ID: 22564257 [TBL] [Abstract][Full Text] [Related]
3. Identification of inhibitor binding site in human sirtuin 2 using molecular docking and dynamics simulations. Sakkiah S; Arooj M; Kumar MR; Eom SH; Lee KW PLoS One; 2013; 8(1):e51429. PubMed ID: 23382805 [TBL] [Abstract][Full Text] [Related]
4. Insight the C-site pocket conformational changes responsible for sirtuin 2 activity using molecular dynamics simulations. Sakkiah S; Arooj M; Cao GP; Lee KW PLoS One; 2013; 8(3):e59278. PubMed ID: 23527151 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and structure-activity relationship studies of novel sirtuin 2 (SIRT2) inhibitors with a benzamide skeleton. Sakai T; Matsumoto Y; Ishikawa M; Sugita K; Hashimoto Y; Wakai N; Kitao A; Morishita E; Toyoshima C; Hayashi T; Akiyama T Bioorg Med Chem; 2015 Jan; 23(2):328-39. PubMed ID: 25515955 [TBL] [Abstract][Full Text] [Related]
6. Virtual screening approach of sirtuin inhibitors results in two new scaffolds. Kokkonen P; Kokkola T; Suuronen T; Poso A; Jarho E; Lahtela-Kakkonen M Eur J Pharm Sci; 2015 Aug; 76():27-32. PubMed ID: 25936698 [TBL] [Abstract][Full Text] [Related]
7. Insight into the Mechanism of Intramolecular Inhibition of the Catalytic Activity of Sirtuin 2 (SIRT2). Li J; Flick F; Verheugd P; Carloni P; Lüscher B; Rossetti G PLoS One; 2015; 10(9):e0139095. PubMed ID: 26407304 [TBL] [Abstract][Full Text] [Related]
8. Crystal structure analysis of human Sirt2 and its ADP-ribose complex. Moniot S; Schutkowski M; Steegborn C J Struct Biol; 2013 May; 182(2):136-43. PubMed ID: 23454361 [TBL] [Abstract][Full Text] [Related]
9. Molecular modelling studies of sirtuin 2 inhibitors using three-dimensional structure-activity relationship analysis and molecular dynamics simulations. Chuang YC; Chang CH; Lin JT; Yang CN Mol Biosyst; 2015 Mar; 11(3):723-33. PubMed ID: 25502412 [TBL] [Abstract][Full Text] [Related]
10. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis. Huang S; Song C; Wang X; Zhang G; Wang Y; Jiang X; Sun Q; Huang L; Xiang R; Hu Y; Li L; Yang S J Chem Inf Model; 2017 Apr; 57(4):669-679. PubMed ID: 28301150 [TBL] [Abstract][Full Text] [Related]
11. Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD Mellini P; Itoh Y; Elboray EE; Tsumoto H; Li Y; Suzuki M; Takahashi Y; Tojo T; Kurohara T; Miyake Y; Miura Y; Kitao Y; Kotoku M; Iida T; Suzuki T J Med Chem; 2019 Jun; 62(12):5844-5862. PubMed ID: 31144814 [TBL] [Abstract][Full Text] [Related]
12. Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases. Borra MT; Langer MR; Slama JT; Denu JM Biochemistry; 2004 Aug; 43(30):9877-87. PubMed ID: 15274642 [TBL] [Abstract][Full Text] [Related]
13. Structure and substrate binding properties of cobB, a Sir2 homolog protein deacetylase from Escherichia coli. Zhao K; Chai X; Marmorstein R J Mol Biol; 2004 Mar; 337(3):731-41. PubMed ID: 15019790 [TBL] [Abstract][Full Text] [Related]
17. Investigation of the catalytic mechanism of Sir2 enzyme with QM/MM approach: SN1 vs SN2? Liang Z; Shi T; Ouyang S; Li H; Yu K; Zhu W; Luo C; Jiang H J Phys Chem B; 2010 Sep; 114(36):11927-33. PubMed ID: 20726530 [TBL] [Abstract][Full Text] [Related]
18. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2. Huhtiniemi T; Suuronen T; Lahtela-Kakkonen M; Bruijn T; Jääskeläinen S; Poso A; Salminen A; Leppänen J; Jarho E Bioorg Med Chem; 2010 Aug; 18(15):5616-25. PubMed ID: 20630764 [TBL] [Abstract][Full Text] [Related]
19. Two-step synthesis of novel, bioactive derivatives of the ubiquitous cofactor nicotinamide adenine dinucleotide (NAD). Pesnot T; Kempter J; Schemies J; Pergolizzi G; Uciechowska U; Rumpf T; Sippl W; Jung M; Wagner GK J Med Chem; 2011 May; 54(10):3492-9. PubMed ID: 21528845 [TBL] [Abstract][Full Text] [Related]
20. In-silico analysis of Sirt2 from Schistosoma mansoni: structures, conformations, and interactions with inhibitors. Singh R; Singh S; Pandey PN J Biomol Struct Dyn; 2016 May; 34(5):1042-51. PubMed ID: 26108803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]